Upgrade to SI Premium - Free Trial

Jazz Pharmaceuticals (JAZZ) PT Raised to $258 at RBC Capital

May 6, 2026 5:24 AM
RBC Capital analyst Leonid Timashev raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $258.00 (from $195.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change